Alimera Sciences and Emory University in exclusive agreement for treatments using antioxidants

Atlanta-Alimera Sciences and Emory University will join together in an agreement to research oxidative stress management. The goal in this endeavor is to treat ophthalmic disease by reducing reactive oxygen species (ROS).

Atlanta-Alimera Sciences and Emory University will join together in an agreement to research oxidative stress management. The goal in this endeavor is to treat ophthalmic disease by reducing reactive oxygen species (ROS).

This agreement exclusively allows Alimera to license a unique class of compounds, which are NADPH oxidase inhibitors, as a potential treatment for conditions such as the dry form of age-related macular degeneration (AMD), specifically the late stage of this condition known as geographic atrophy.

Evidence verifies oxidative stress as a key aspect in both disease development and progression. The increased levels of ROS, which result from oxidative stress, also contribute to certain pathologic conditions, including dry AMD.

Alimera has an exclusive worldwide license for the NADPH oxidase inhibitor for ophthalmic indications. Also included in the agreement is an exclusive right to sublicense in ophthalmology and the exclusive option for non-ophthalmic use. Alimera will be in charge of development and commercialization, and Emory will receive milestone payments and royalties from net sales.